|
|
Scientific
Session...
October
17, 2000
|
|
9.30 a.m.
|
MONOCLONAL
ANTIBODY THERAPY II
Chronic
lymphocytic leukemia and other lymphoproliferative
disorders.
Chairmen M. Brugiatelli, G.L. Castoldi
-Rituximab and Campath 1-H in the treatment of chronic
lymphocytic leukemia. M. Brugiatelli presenting M.J. Keating' slides
-Monoclonal antibody therapy for immunocytoma, small
lymphocytic lymphoma and hairy cell leukemia. M.
Federico
-Monoclonal antibody therapy in the treatment of
AIDS-related lymphoma. U. Tirelli
|
|
11.00 a.m.
|
Panel
discussion chaired by
M. Brugiatelli, G.L. Castoldi:
Hopes
for the future
|
|
11.30 a.m.
|
Coffe Break
|
|
11.45 a.m.
|
MONOCLONAL
ANTIBODY THERAPY III
Application
of antibody-targeted chemotherapy in
AML. Chairmen
F. Mandelli, G. Torelli
-Overview on CMA-676 experience and novel applications.
F. De Tomasi
-Efficacy and safety of CMA-676 in AML patients in first
relapse. E.L. Sievers
-EORTC/GIMEMA Study. S. Amadori
|
|
1.00 p.m.
|
Panel
discussion chaired by
F. Mandelli, G. Torelli:
Future
applications of antibody-targeted chemotherapy in acute
myeloid leukemia
|
|
1.30 p.m.
|
Conclusive
remarks G.
Torelli
|
|
1.40 p.m.
|
Lunch
|
|
|
|